UCB

Biotechnology / Pharmaceuticals

UCB.BR

€ 105 8.1

Share price

$ 22 bn

Market Cap

$ 23 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.06x the weighted average for S&P 500

FY2021

Primary Climate Goal

UCB aims to reduce all Scopes by 38% by 2030 from a base year 2015

<2°C

GHG emissions and Carbon intensity

UCB reported Total CO2e Emissions - Location-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 46 Kt (-2.5 /-5.2% y-o-y). Also positively, carbon intensity declined to 7.1 t (-1.1 /-13.4% y-o-y).

UCB's Scope 3 emissions decreased to 34 Kt (-4.2 /-11% y-o-y). The rate of decline has slowed vs. the previous periods (CAGR -17% since 4Q'15).

The company has not set a company-wide target for an absolute reduction in GHG emissions yet.

Date	Total CO2e emissions (location-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2021Q4	46	28	18	34	6,493	7.1
2020Q4	49	31	18	38	5,916	8.2
2019Q4	59	40	18	79	5,260	11
2018Q4	62	42	21	85	5,216	12
2015Q4		56		86

UCB

Carbon footprint

Primary Climate Goal

UCB aims to reduce all Scopes by 38% by 2030 from a base year 2015

GHG emissions and Carbon intensity

UCB's carbon footprint

Company environmental metrics